BY TAIWO OGUNMOLA -OMILANI
The Director-General of the National Agency for Food and Drug Administration and Control (NAFDAC), Prof. Mojisola Adeyeye, has called on international partners to support the establishment of vaccine manufacturing facilities in Nigeria.
Adeyeye made the call at the 8th Nigeria Pharma Manufacturers’ Expo, jointly organised in Lagos by the Pharmaceutical Manufacturing Group of the Manufacturers Association of Nigeria (PMG-MAN) and PGE Expo PVT Limited.
She acknowledged the continued support of international partners in NAFDAC’s journey towards attaining Maturity Level 3, urging them to contribute to the establishment of a fill-and-finish modular vaccine manufacturing facility in Nigeria.
According to her, NAFDAC has nine functions and requirements to meet to become fully benchmarked for medicines and vaccines, adding that the agency had been benchmarked in eight, with the final requirement being Lot Release for vaccines.
“We want to call on our international partners that have been of tremendous help. Without them, we wouldn’t have been here.
I want to challenge them to contribute to fill-and-finish modular vaccine manufacturing so that we can get our Vaccine Lot Release,” she said.
Adeyeye said Nigeria had all it needed to attain Maturity Level 4, except for local vaccine manufacturing.
“To get Lot Release—Maturity Level 4—we have figured it out in a way we have estimated. It’s not going to cost too much. We will share that with you because we cannot afford to go back to where we used to be,” she said.
The NAFDAC boss recalled that the agency previously manufactured vaccines, saying, “It’s high time we went back to vaccine manufacturing.”
She also commended President Bola Ahmed Tinubu for the Executive Order of 2024, which she said provided incentives for local pharmaceutical manufacturers operating under difficult economic conditions.
“I understand the stress our manufacturers are going through.
Our manufacturers are patriots because they could have given up. I was championing incentives for the manufacturers until President Tinubu came on board with the Executive Order of 2024,” she said.
She added that the Coordinating Minister of Health and Social Welfare and the Minister of State for Health at the time also supported the need for incentives, which contributed to the initiative to unlock the value chain.
Adeyeye said NAFDAC’s efforts to improve local pharmaceutical manufacturing began with its Good Manufacturing Practice (GMP) Roadmap, under which NAFDAC inspectors conducted GMP compliance audits of more than 165 companies over eight months.
She said the initiative was funded by USAID and executed by the United States Pharmacopeia.
“We started the journey of not just the industry making products but making quality products because this is intricately tied to the patient’s positive health outcomes during treatment. There would not be treatment failure,” she said.
Adeyeye, however, clarified that the GMP compliance audits were conducted during routine inspections and not under the roadmap.
She said data from 2021 to 2025 showed a 70 per cent reduction in the importation of products under the “5 plus 5” and Ceiling Initiative, attributing the development to local manufacturers taking up the challenge of producing more pharmaceutical products locally.
She said manufacturers had demonstrated commitment to making the health of Nigerians a priority while improving their standing in the international market through quality products.
Adeyeye noted that the progress was also made possible by NAFDAC’s efforts to improve the competence of its staff, stressing that “you cannot give what you don’t have.”
She added that the agency had received recognition from international institutions, including becoming a member of the International Medical Device Regulators Forum in 2023, while its laboratory in Yaba became WHO-prequalified in September 2023.
The NAFDAC boss explained that the World Health Organisation does not award Maturity Level 3 as a one-off achievement, but returns to re-benchmark regulatory agencies to ensure they remain strong, consistent and resilient.
She said NAFDAC became the first agency in sub-Saharan Africa to be successfully re-benchmarked the first time.
“All this is because of our industry. It’s because of our citizens,” she said, adding that NAFDAC is one of 194 regulatory agencies across the world and is judged by the same standards irrespective of the size or economic status of its country.
The Chairman of PMG-MAN, Mr Oluwatosin Jolayemi, said the expo was the only platform for a complete pharmaceutical manufacturing exhibition in Central and West Africa, bringing together manufacturers, regulators, investors, development partners and other stakeholders.
He said the expo provided an opportunity to showcase industry capabilities, forge partnerships and shape the future of the pharmaceutical manufacturing sector.
Jolayemi, who is also the Managing Director/CEO of Daily-Need Manufacturing Company Limited, commended Adeyeye for her efforts towards ensuring that the industry moves in line with international best practices in quality and GMP compliance.
He said NAFDAC’s policies were beginning to change the pharmaceutical manufacturing ecosystem, stressing that the gains must be sustained.
He, however, called for an extension of the presidential Executive Order for another two years when it expires in March 2027, arguing that the journey towards medicine security and pharmaceutical sovereignty requires policy consistency, investment, capacity development and a predictable operating environment.
A total of 132 companies from the United States, China, Argentina, Egypt, India, Rwanda, Austria, the United Arab Emirates, France, Germany, Indonesia and Nigeria, among others, participated in the two-day expo.